Improved survival of follicular lymphoma patients in the United States

被引:222
作者
Swenson, WT
Wooldridge, JE
Lynch, CF
Forman-Hoffman, VL
Chrischilles, E
Link, BK
机构
[1] Univ Iowa, Coll Med, Dept Internal Med, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa City, IA 52242 USA
[2] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA
关键词
D O I
10.1200/JCO.2005.04.503
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Despite several new treatment options, single- and multi-institution analyses have not clarified whether survival patterns in follicular lymphoma (FL) patients have changed in recent decades. We undertook a study using a large population-based registry to analyze survival patterns among patients with FL. Patients and Methods Surveillance, Epidemiology, and End Results morphology codes were used to identify 14,564 patients diagnosed with FL between 1978 and 1999. Observed median survival times, Kaplan-Meier survival curves, proportional death hazard ratios, and relative survival rates were calculated. Joinpoint regression analysis was used to identify trends in annual adjusted death hazard ratios. Results An improvement in survival of all patients with FL was observed between each of three diagnosis eras (1978 to 1985, 1986 to 1992, and 1993 to 1999) by log-rank tests. Among patients with stage-specific data, the median survival time improved from 84 months (95% CI, 81 to 88 months) in the 1983 to 1989 era to 93 months (95% CI, 89 to 97 months) in the 1993 to 1999 era. Similar findings were identified across sex and age groups and for subsets including advanced-stage, large-cell FL and the combined subset of small cleaved- and mixed-cell FL. The inter-era survival advantage observed in white patients was not observed for black patients. The relative risk of death decreased by 1.8% per year over the 1983 to 1999 observation period. Conclusion The survival of patients with FL in the United States has improved over the last 25 years. The survival improvement may be a result of the sequential application of effective therapies and improved supportive care.
引用
收藏
页码:5019 / 5026
页数:8
相关论文
共 29 条
[1]  
Allison P.D., 1999, LOGISTIC REGRESSION
[2]  
Allison PD., 2010, SURVIVAL ANAL USING
[3]  
American Cancer Society, 1968, MAN TUM NOM COD
[4]  
[Anonymous], SURV EP END RES SEER
[5]  
[Anonymous], INT CLASS DIS ONC
[6]   Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial [J].
Ardeshna, KM ;
Smith, P ;
Norton, A ;
Hancock, BW ;
Hoskin, PJ ;
MacLennan, KA ;
Marcus, RE ;
Jelliffe, A ;
Hudson, GV ;
Linch, DC .
LANCET, 2003, 362 (9383) :516-522
[7]   A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma [J].
Brandt, L ;
Kimby, E ;
Nygren, P ;
Glimelius, B .
ACTA ONCOLOGICA, 2001, 40 (2-3) :213-223
[8]  
Chan WC, 1997, BLOOD, V89, P3909
[9]   Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: Reliability of diagnosis and subtype classifications [J].
Clarke, CA ;
Glaser, SL ;
Dorfman, RF ;
Bracci, PM ;
Eberle, E ;
Holly, EA .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (01) :138-143
[10]  
DICK F, 1987, J NATL CANCER I, V78, P1137